Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

about

Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

Item

http://www.wikidata.org/entity/Q36361377

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Cost-effectiveness analysis of ...... chronic hepatitis B in Turkey

@ast

Cost-effectiveness analysis of ...... chronic hepatitis B in Turkey

@en

type

Item

label

Cost-effectiveness analysis of ...... chronic hepatitis B in Turkey

@ast

Cost-effectiveness analysis of ...... chronic hepatitis B in Turkey

@en

prefLabel

Cost-effectiveness analysis of ...... chronic hepatitis B in Turkey

@ast

Cost-effectiveness analysis of ...... chronic hepatitis B in Turkey

@en

P1476

Cost-effectiveness analysis of ...... chronic hepatitis B in Turkey

@en

P2093

Akin Kose

http://www.w3.org/2001/XMLSchema#string

Ece Kucuksayrac

http://www.w3.org/2001/XMLSchema#string

Fatma Betul Yenilmez

http://www.w3.org/2001/XMLSchema#string

Guvenc Kockaya

http://www.w3.org/2001/XMLSchema#string

Oktay Ozdemir

http://www.w3.org/2001/XMLSchema#string

P2860

Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review

Telbivudine versus lamivudine in patients with chronic hepatitis B

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Update on diagnosis, management, and prevention of hepatitis B virus infection.

Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections.

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

P2888

s12962-015-0046-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12962-015-0046-8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286484788

http://www.w3.org/2001/XMLSchema#string

P6179

1018570245

http://www.w3.org/2001/XMLSchema#string

P698

26664289

http://www.w3.org/2001/XMLSchema#string

P932

4674927

http://www.w3.org/2001/XMLSchema#string